N-Methyllidocaine iodideCAS# 1462-71-1 |
2D Structure
- SU14813
Catalog No.:BCC1971
CAS No.:627908-92-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 1462-71-1 | SDF | Download SDF |
PubChem ID | 121114 | Appearance | Powder |
Formula | C15H25IN2O | M.Wt | 376.28 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | QX 372, N-Methyllignocaine iodide | ||
Solubility | Soluble to 50 mM in water | ||
Chemical Name | [2-(2,6-dimethylanilino)-2-oxoethyl]-ethyl-dimethylazanium;iodide | ||
SMILES | CC[N+](C)(C)CC(=O)NC1=C(C=CC=C1C)C.[I-] | ||
Standard InChIKey | OBZFQPPTRWTILY-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C14H22N2O.HI/c1-6-16(4,5)10-13(17)15-14-11(2)8-7-9-12(14)3;/h7-9H,6,10H2,1-5H3;1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Antiarrhythmic. Enhances the biosynthesis of phosphatidylinositol in hamster heart. |
N-Methyllidocaine iodide Dilution Calculator
N-Methyllidocaine iodide Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.6576 mL | 13.288 mL | 26.576 mL | 53.1519 mL | 66.4399 mL |
5 mM | 0.5315 mL | 2.6576 mL | 5.3152 mL | 10.6304 mL | 13.288 mL |
10 mM | 0.2658 mL | 1.3288 mL | 2.6576 mL | 5.3152 mL | 6.644 mL |
50 mM | 0.0532 mL | 0.2658 mL | 0.5315 mL | 1.063 mL | 1.3288 mL |
100 mM | 0.0266 mL | 0.1329 mL | 0.2658 mL | 0.5315 mL | 0.6644 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Chlorajapolide F
Catalog No.:BCN6425
CAS No.:1461760-59-7
- R-(-)-Deprenyl hydrochloride
Catalog No.:BCC5196
CAS No.:14611-52-0
- Z-Arg(Z)2-OH
Catalog No.:BCC3574
CAS No.:14611-34-8
- Pulchinenoside E1
Catalog No.:BCN8185
CAS No.:146100-02-9
- Dihydromarein
Catalog No.:BCN8406
CAS No.:
- MSDC-0160
Catalog No.:BCC5343
CAS No.:146062-49-9
- Tauroursodeoxycholic acid
Catalog No.:BCN6953
CAS No.:14605-22-2
- SC 51089
Catalog No.:BCC7773
CAS No.:146033-02-5
- SC 51322
Catalog No.:BCC5941
CAS No.:146032-79-3
- Tropine nonanoate
Catalog No.:BCN1925
CAS No.:146018-90-8
- 2-Fluoroadenosine
Catalog No.:BCC8576
CAS No.:146-78-1
- 2-Chloroadenosine
Catalog No.:BCC7575
CAS No.:146-77-0
- SR 48692
Catalog No.:BCC7763
CAS No.:146362-70-1
- Desmethylrocaglamide
Catalog No.:BCN7735
CAS No.:146408-78-8
- Lactose
Catalog No.:BCN8387
CAS No.:14641-93-1
- Flavopiridol
Catalog No.:BCC1577
CAS No.:146426-40-6
- Camaric acid
Catalog No.:BCN1650
CAS No.:146450-83-1
- Pralatrexate
Catalog No.:BCC2304
CAS No.:146464-95-1
- 1-Methylpsilocin
Catalog No.:BCC7536
CAS No.:1465-16-3
- Complanatoside A
Catalog No.:BCN6282
CAS No.:146501-37-3
- WR 1065
Catalog No.:BCC2417
CAS No.:14653-77-1
- Tyrphostin AG 1296
Catalog No.:BCC1195
CAS No.:146535-11-7
- Fmoc-Gly(allyl)-OH
Catalog No.:BCC3156
CAS No.:146549-21-5
- 2-Cyclopropyl-3-[(diphenylphosphinyl)methyl]-4-(4-fluorophenyl)quinoline
Catalog No.:BCC8572
CAS No.:146578-99-6
Palmoplantar pustulosis and pustulotic arthro-osteitis treatment with potassium iodide and tetracycline, a novel remedy with an old drug: a review of 25 patients.[Pubmed:28369847]
Int J Dermatol. 2017 Aug;56(8):889-893.
BACKGROUND: The use of potassium iodide (KI) to treat palmoplantar pustulosis (PPP) and pustulotic arthro-osteitis (PAO) has not previously been reported. Here, we report the first successful treatment of PPP and PAO with KI. PATIENT AND METHODS: Among 25 patients with PPP, seven had an associated PAO. All patients were administered 900 mg KI three times per day for 3 months. Overall, 12 patients received this medical treatment for the first time or had >6 months interval since the last therapy for PPP. The other 13 patients who were nonresponsive to tetracycline for >3 months prior to KI treatment were treated with a combination of KI and tetracycline. All seven patients with PAO were included in the tetracycline and KI-treated group. RESULTS: More than 70% of patients demonstrated complete clearance or >/=50% improvement in palmoplantar pustular psoriasis area and severity index (PPPASI) from baseline. In the group with <50% improvement in PPPASI from baseline, all except one patient were smokers. In the KI with tetracycline treatment group, approximately 80% demonstrated improvement. At the end of 3 months, there was remission of arthralgia in five out of seven PPP patients with PAO. CONCLUSIONS: Treatment with KI and/or its combination with tetracycline may be a useful treatment for PPP/PAO. Smoking may affect the effectiveness of these treatment modalities.
Tetranuclear Copper(I) Iodide Complexes: A New Class of X-ray Phosphors.[Pubmed:28375624]
Inorg Chem. 2017 Apr 17;56(8):4610-4615.
We report intensive visible light radioluminescence upon X-ray irradiation of archetypal tetranuclear copper(I) iodide complexes containing triphenylphosphine or pyridine ligands in the solid state. These properties, attractive for the design of X-ray responsive materials, can be attributed to the heavy {Cu4I4} cubane-like core, the absence of oxygen quenching of the emissive triplet states, and the high photoluminescence quantum yields. Radioluminescence originates from the same emissive triplet states as those produced by ultraviolet excitation as confirmed by the observed radioluminescence thermochromism. The radioluminescence properties are also preserved after incorporation of these complexes into polystyrene films, making them appealing for the development of plastic scintillators.
Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene.[Pubmed:28380420]
Oncotarget. 2017 May 16;8(20):33393-33404.
The theranostic sodium iodide symporter (NIS) gene allows detailed molecular imaging of transgene expression and application of therapeutic radionuclides. As a crucial step towards clinical application, we investigated tumor specificity and transfection efficiency of epidermal growth factor receptor (EGFR)-targeted polyplexes as systemic NIS gene delivery vehicles in an advanced genetically engineered mouse model of pancreatic ductal adenocarcinoma (PDAC) that closely reflects human disease. PDAC was induced in mice by pancreas-specific activation of constitutively active KrasG12D and deletion of Trp53. We used tumor-targeted polyplexes (LPEI-PEG-GE11/NIS) based on linear polyethylenimine, shielded by polyethylene glycol and coupled with the EGFR-specific peptide ligand GE11, to target a NIS-expressing plasmid to high EGFR-expressing PDAC. In vitro iodide uptake studies in cell explants from murine EGFR-positive and EGFR-ablated PDAC lesions demonstrated high transfection efficiency and EGFR-specificity of LPEI-PEG-GE11/NIS. In vivo 123I gamma camera imaging and three-dimensional high-resolution 124I PET showed significant tumor-specific accumulation of radioiodide after systemic LPEI-PEG-GE11/NIS injection. Administration of 131I in LPEI-PEG-GE11/NIS-treated mice resulted in significantly reduced tumor growth compared to controls as determined by magnetic resonance imaging, though survival was not significantly prolonged. This study opens the exciting prospect of NIS-mediated radionuclide imaging and therapy of PDAC after systemic non-viral NIS gene delivery.
Tracking dendritic cell migration into lymph nodes by using a novel PET probe (18)F-tetrafluoroborate for sodium/iodide symporter.[Pubmed:28378292]
EJNMMI Res. 2017 Dec;7(1):32.
BACKGROUND: Recently, (18)F-tetrafluoroborate (TFB) was used as a substrate for the human sodium/iodide symporter (hNIS) reporter gene. This study evaluated the feasibility of performing molecular-genetic imaging by using the new radiotracer ((18)F-TFB) for the hNIS gene, to track dendritic cell (DC) migration in live mice. A murine dendritic cell line (DC2.4) co-expressing the hNIS and effluc genes (DC/NF) was established. To confirm the functional cellular expression of both effluc and NIS in the inoculated DC/NF cells by bio-medical imaging, combined bioluminescence imaging (BLI) and (18)F-TFB positron emission tomography/computed tomography (PET/CT) imaging was performed after intramuscular injection with parental DCs and DC/NF cells. For DC-tracking, parental DCs or DC/NF cells were injected in the left or right mouse footpad, respectively, and (18)F-TFB PET/CT and BLI were performed to monitor these cells in live mice. RESULTS: In vivo PET/CT and BLI showed a clear signal in DC/NF injection sites but not in parental DC injection sites. The signal intensity in DC/NF cells was correlated with time. In vivo (18)F-TFB PET/CT imaging showed higher radiotracer activity in the draining popliteal lymph nodes (DPLNs) in DC/NF injection sites than those in DC injection sites on day 2. BLI also showed DC/NF cell migration to the DPLNs on day 2 after the injection. CONCLUSIONS: Migration of DCs to the lymph nodes was successfully monitored using (18)F-TFB PET/CT imaging of the NIS gene and optical imaging of the effluc gene in live mice. These data support the feasibility of using (18)F-TFB as a substrate for hNIS reporter gene imaging to track the migration of DCs to the lymph nodes in live animals. The use of (18)F-TFB may facilitate enhanced PET imaging of the hNIS reporter gene in small animals and humans in future studies.
The modulation of phosphatidylinositol biosynthesis in hamster hearts by methyl lidocaine.[Pubmed:7639704]
Biochem J. 1995 Aug 1;309 ( Pt 3):871-6.
Methyl lidocaine is an experimental anti-arrhythmic drug which has been shown to enhance the biosynthesis of phosphatidyl-inositol (PI) in the hamster heart. In this study, the effect of methyl lidocaine on enzymes involved in the biosynthesis of PI in the heart was examined. When the hamster heart was perfused with labelled methyl lidocaine, the majority of the compound was not metabolized after perfusion. The direct action of methyl lidocaine on an enzyme was studied by the presence of the drug in enzyme assays, whereas its indirect action was studied by assaying the enzyme activity in the heart after methyl lidocaine perfusion. CTP:phosphatidic acid cytidylyl-transferase, a rate-limiting enzyme in PI biosynthesis, was stimulated by methyl lidocaine in a direct manner. Kinetic studies revealed that methyl lidocaine caused a change in the affinity between the enzyme and phosphatidic acid and resulted in the enhancement of the reaction. Alternatively, acyl-CoA:lysophosphatidic acid acyltransferase, another key enzyme for PI biosynthesis, was not activated by the presence of methyl lidocaine. However, the enzyme activity was stimulated in hearts perfused with methyl lidocaine. The enhancement of the acyl-transferase by methyl lidocaine perfusion was found to be mediated via the adenylate cyclase cascade with the elevation of the cyclic AMP level. The stimulation of protein kinase A activity by cyclic AMP resulted in the phosphorylation and activation of the acyltransferase. Interestingly, the activity of protein kinase C was not stimulated by methyl lidocaine perfusion. We conclude that the enhancement of PI biosynthesis by methyl lidocaine in the hamster heart resulted from the direct activation of the cytidylyltransferase, as well as the phosphorylation and subsequent activation of the acyltransferase.
The effect of methyl-lidocaine on the biosynthesis of phospholipids de novo in the isolated hamster heart.[Pubmed:1322123]
Biochem J. 1992 Jul 1;285 ( Pt 1):161-6.
Methyl-lidocaine is an amphiphilic agent which has been used as an experimental anti-arrhythmic drug. When hamster hearts were perfused with labelled glycerol, the presence of methyl-lidocaine in the perfusate was found to enhance the labelling in phosphatidylserine, phosphatidylinositol, diacylglycerol and triacylglycerol. However, the labelling of phosphatidylcholine and phosphatidylethanolamine was not significantly changed by methyl-lidocaine treatment. Assays in vitro for the enzymes involved in the synthesis of neutral lipids and acidic phospholipids revealed that phosphatidate phosphatase and CTP: phosphatidate cytidylyltransferase activities were stimulated by methyl-lidocaine. The intracellular pool sizes of diacylglycerol and CDP-diacylglycerol were also elevated. We postulate that the enhanced syntheses of the neutral lipids and acidic phospholipids in the methyl-lidocaine-perfused heart were mediated via the direct activation of the key enzymes in the biosynthesis of these lipids de novo.